Interleukin-1β Is Differentially Expressed by Human Dermal Papilla Cells in Response to PKC Activation and Is a Potent Inhibitor of Human Hair Follicle Growth in Organ Culture

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

A new topical compound for hair loss, claimed to be developed by Jeff Vincint, is being discussed. It reportedly doesn't use minoxidil or finasteride, and there is skepticism about its legitimacy.

The user is disappointed with the lack of visible progress in hair regrowth after 6 months of using finasteride and minoxidil. Another user suggests adding a topical anti-androgen like kx826, while encouraging patience as changes may start to show between 6-9 months.

The user experienced significant hair regrowth using 1+ mg of finasteride and 2.5 mg of minoxidil, later increasing to 5 mg, along with dermarolling. They reported no negative side effects and noted improved libido.

Stopping Dutasteride may temporarily affect sperm quality, but it typically returns to normal within a few months. Minoxidil and Dutasteride are used for hair maintenance, and Mucuna Pruriens and hCG are suggested for improving sperm quality.

The user experienced hair regrowth and stopped hair loss after taking finasteride three times a week without side effects. Discussion included the importance of scalp sensitivity to DHT and the use of topical dutasteride.